Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer... Show more
PPBT saw its Momentum Indicator move below the 0 level on February 25, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned negative. In of the 87 cases, the stock moved further down in the following days. The odds of a decline are at .
The Moving Average Convergence Divergence Histogram (MACD) for PPBT turned negative on March 03, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPBT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for PPBT entered a downward trend on March 04, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PPBT advanced for three days, in of 259 cases, the price rose further within the following month. The odds of a continued upward trend are .
PPBT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.254) is normal, around the industry mean (11.936). P/E Ratio (0.049) is within average values for comparable stocks, (64.881). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.794). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (235.669).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PPBT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PPBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
a provider of pharmaceutical drug discovery and development services
Industry Biotechnology
A.I.dvisor indicates that over the last year, PPBT has been loosely correlated with SNTI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if PPBT jumps, then SNTI could also see price increases.
Ticker / NAME | Correlation To PPBT | 1D Price Change % | ||
---|---|---|---|---|
PPBT | 100% | +4.15% | ||
SNTI - PPBT | 54% Loosely correlated | +10.07% | ||
BCYC - PPBT | 32% Poorly correlated | +2.37% | ||
ORYZF - PPBT | 29% Poorly correlated | N/A | ||
RLMD - PPBT | 27% Poorly correlated | -1.45% | ||
CCCC - PPBT | 27% Poorly correlated | +2.10% | ||
More |
Ticker / NAME | Correlation To PPBT | 1D Price Change % |
---|---|---|
PPBT | 100% | +4.15% |
drugs theme (248 stocks) | 10% Poorly correlated | +1.92% |
pharmaceuticals theme (157 stocks) | 7% Poorly correlated | +1.86% |
middle east theme (69 stocks) | 5% Poorly correlated | +2.53% |